NCT07283692 Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
| NCT ID | NCT07283692 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | RenJi Hospital |
| Condition | Triple Negative Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 46 participants in total. It began in 2026-03-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Eligibility Criteria
Inclusion Criteria: * Female, Aged ≥18 and ≤70 years * Histologically confirmed triple negative breast cancer (ER\<10%, PR\<10%, and HER2 negative) * Subjects with at least one evaluable lesion * ECOG 0-1 * Adequate organ function Exclusion Criteria: * Metastatic disease (Stage IV) * Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Contact & Investigator
Wenjin Yin, M.D.
PRINCIPAL INVESTIGATOR
Renji Hospital,School of Medicine, Shanghai Jiaotong University
Frequently Asked Questions
Who can join the NCT07283692 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Triple Negative Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07283692 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07283692 currently recruiting?
Yes, NCT07283692 is actively recruiting participants. Contact the research team at yinwenjin@renji.com for enrollment information.
Where is the NCT07283692 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07283692 clinical trial?
NCT07283692 is sponsored by RenJi Hospital. The principal investigator is Wenjin Yin, M.D. at Renji Hospital,School of Medicine, Shanghai Jiaotong University. The trial plans to enroll 46 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.